← All trials
NCT05619653
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2028
- First posted
- Nov 17, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- J. W. Goethe UniversityLead sponsor
- BayerCollaborator
- J. W. Goethe UniversityOverall official - principal investigator
- J. W. Goethe UniversitySponsor investigator
- Alcedis GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.